ResearcherSemmelweis UniversityActive in the last 2 years
Zsófia A. Szász
Matched on ORCID iD 0009-0000-3110-0379; OpenAlex author ID A5072742313.
Their work
- Papers
- 3 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Collaborators
- 4
2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper
Papers 3
- Comparative study of the anti-tumour effects of the imipridone, ONC201 and its fluorinated analogues on pancreatic cancer cell line. First author DOI 10.1038/s41598-025-00070-x↗
- Characterisation of the cell and molecular biological effect of peptide-based daunorubicin conjugates developed for targeting pancreatic adenocarcinoma (PANC-1… First author DOI 10.1016/j.biopha.2024.116293↗
- [Comparison of therapeutic peptides targeting pancreatic cancer]. Co-author PMID 31821385↗
Closest collaborators
The 4 strongest of 4 ranked by shared papers, trials and grants, with recent and small-team work weighing most.
- Eszter Lajkó · 3 shared papers, 2019–2025
- Paper Comparative study of the anti-tumour effects of the imipridone, ONC201 and its fluorinated analogues on pancreatic canc… DOI 10.1038/s41598-025-00070-x↗
- Paper Characterisation of the cell and molecular biological effect of peptide-based daunorubicin conjugates developed for tar… DOI 10.1016/j.biopha.2024.116293↗
- Paper [Comparison of therapeutic peptides targeting pancreatic cancer]. PMID 31821385↗
- László Kőhidai · 3 shared papers, 2019–2025
- Paper Comparative study of the anti-tumour effects of the imipridone, ONC201 and its fluorinated analogues on pancreatic canc… DOI 10.1038/s41598-025-00070-x↗
- Paper Characterisation of the cell and molecular biological effect of peptide-based daunorubicin conjugates developed for tar… DOI 10.1016/j.biopha.2024.116293↗
- Paper [Comparison of therapeutic peptides targeting pancreatic cancer]. PMID 31821385↗
- Gábor Mező · 2 shared papers, 2019–2024
- Levente Endre Dókus · 1 shared paper, 2019
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.